Test trial of spike‐in immunoglobulin heavy‐chain (<i>IGH</i>) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia

Giusti, Guilherme Navarro Nilo; Jotta, Patricia Yoshioka; Lopes, Caroline de Oliveira; Ganazza, Mônica Aparecida; Azevedo, Amílcar Cardoso de; Brandalise, Sílvia Regina; Meidânis, João; Yunes, José Andrés

doi:10.1111/bjh.16571

Cited by 5 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 Other authors used plasmids as calibrators. 43,48 Since plasmids did not provide a stable performance in our experience, gBlocks were designed for this purpose. The choice of adding 10 molecules of the three different gBlocks each (30 molecules in total) was based on the fact that this would reflect approximately 0.03% of MRD if 10 5 cells (approximately 600 ng of DNA) were tested, an amount that should be reliably quantified in a good MRD assay.…”

Section: Discussionmentioning

confidence: 99%

Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators

Straeten

Brouwer

Kabongo

et al. 2021

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators

Straeten

Brouwer

Kabongo

et al. 2021

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

“…These control clonotypes are then used to establish a cell/read ratio for the sample, which in turn is used to find the number of cells for leukemia clonotypes. In recent years, protocols for this purpose have been established by several groups, with one of the most comprehensive and prominent examples being released by the EuroClonality‐NGS group [4–8].…”

Section: Figurementioning

confidence: 99%

“…In recent years, protocols for this purpose have been established by several groups, with one of the most comprehensive and prominent examples being released by the EuroClonality-NGS group [4][5][6][7][8].…”

mentioning

confidence: 99%

“…The number of different cIT-QC control molecules Vidjil identified for each sample was also analyzed. While the cIT-QC system consists of 46 different control molecules in total, only a few of them (3)(4)(5)(6)(7)(8)(9)(10)(11) are expected to be found in each sample, since according to the EuroClonality-NGS protocol each marker undergoes PCR for library preparation in different tubes with its own set of primers. In this context, Vidjil was able to identify all expected cIT-QC sequences in 25/32 samples (78.1%), while ARResT/Interrogate did so in 29/32 samples (90.6%).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Vidjil add‐on for MRD quantification of samples processed using the EuroClonality‐NGS protocol

Giusti

Ribeiro

Jotta

et al. 2023

eJHaem

Self Cite

View full text Add to dashboard Cite

Assessment of minimal residual disease in acute lymphoblastic leukemia by immune repertoire NGS requires spiking CDR3 sequences at known quantities into the patient's sample. Recently, the EuroClonality‐NGS group released one of the most comprehensive protocols for this purpose. ARResT/Interrogate is a closed‐source software for processing these NGS libraries, developed by this same group. Vidjil, an open‐source alternative, currently cannot handle libraries prepared using this protocol. Here, we present a Vidjil add‐on to solve this issue. EuroClonality‐NGS prepared samples analyzed with Vidjil and ARResT/Interrogate were highly concordant (r = 0.998) and presented low error (root‐mean‐square error, RMSE = 0.112).

show abstract

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Liu,

Ho,

et al. 2024

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

Test trial of spike‐in immunoglobulin heavy‐chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia

Cited by 5 publications

References 11 publications

Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators

Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators

Vidjil add‐on for MRD quantification of samples processed using the EuroClonality‐NGS protocol

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Contact Info

Product

Resources

About